Teva Defeats Infringement Claims on Endocrine Drug

“A Camden, New Jersey, federal judge ruled that Teva Pharmaceuticals USA Inc.’s application to make a generic version of a drug called Korlym did not infringe on patents on the drug that are held by Corcept Therapeutics.

The ruling allows Teva, an Israeli company whose U.S. headquarters is in Parsippany, New Jersey, to proceed with plans to sell its own version of Korlym.”

Sterne, Kessler, Goldstein & Fox was mentioned as Teva’s representation in the article “Teva Defeats Infringement Claims on Endocrine Drug,” published by the New Jersey Law Journal. Directors John Christopher Rozendaal, Uma N. Everett, William H. Milliken, Anna G. Phillips, and associates Brady P. Gleason, Brooke McLain and Ryan Kaiser represent Teva.